Private investors: FCPR

We apply our knowledge of French SMEs to help private investors who are looking for high-performance and meaningful investments

Private equity accessible to individual investors

  • Through its FCPR (“Fonds Communs de Placement à Risque”) range of private equity funds, Omnes Capital gives individual investors access to an asset class usually reserved for institutional investors.

Boost portfolio returns

  • Invest in unlisted SMEs that create wealth and employment
  • Diversify financial assets: recommended allocation for private equity - 5% of a portfolio
  • Achieve solid long-term performance: the class has outperformed the CAC 40 index by 5.2% over the past 10 years
  • Secure tax incentives: sales exempt from capital gains tax

Omnes’ expertise

  • 15 years’ experience
  • Rigorous selection of SMEs: high-performance French companies with a leadership position in their sector, genuine growth prospects, solid fundamentals and seasoned management team
  • Reasonable leverage and value creation underpinned by growth in portfolio companies net revenues
  • Strong entrepreneurial culture among management teams, who share the same vision as company executives
  • Direct access to the management team
  • Meetings with portfolio companies entrepreneurs and detailed reporting provided
Key figures
15
years’
experience
5
funds
dedicated to private investors
NewsRoom
Press release
11 April 2019
NH TherAguix, a start-up specializing in nanomedicine for cancer radiotherapy, announces a €13 million round of fundraising, led by Bpifrance

NH TherAguix, a start-up specializing in nanomedicine for cancer radiotherapy, announces a €13 million round of fundraising, led by Bpifrance
3 minutes for innovation - FCPI innovation funds : Omnes' new investments
Publication
Scope, the Omnes review, November 2018
Press release
09 April 2019
Appointments within Omnes: Omnes welcomes five newcomers as Director, Principal, Analyst, Middle Office Managers, and promotes four Principals
Appointments within Omnes: Omnes welcomes five newcomers as Director, Principal, Analyst, Middle Office Managers, and promotes four Principals
Press release
03 April 2019
AgomAb Therapeutics Completes Euros 21m Series A Financing
AgomAb Therapeutics Completes Euros 21m Series A Financing
Press release
19 March 2019
Omnes announces a 15% investor net IRR on its Capenergie 2 fund, focused on renewable energy

Omnes announces a 15% investor net IRR on its Capenergie 2 fund, focused on renewable energy

Pages